Cargando…

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab

Squamous cell carcinoma of the head and neck (SCCHN) is a prevalent disease both in the United States and worldwide with an overall poor prognosis, in part due to limited activity of existing therapy. Primary therapy is largely dictated by the anatomical origin of the cancer and whether distant dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Kono, Scott A., Haigentz, Missak, Yom, Sue S., Saba, Nabil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465896/
https://www.ncbi.nlm.nih.gov/pubmed/23056941
http://dx.doi.org/10.1155/2012/901320
_version_ 1782245606631145472
author Kono, Scott A.
Haigentz, Missak
Yom, Sue S.
Saba, Nabil
author_facet Kono, Scott A.
Haigentz, Missak
Yom, Sue S.
Saba, Nabil
author_sort Kono, Scott A.
collection PubMed
description Squamous cell carcinoma of the head and neck (SCCHN) is a prevalent disease both in the United States and worldwide with an overall poor prognosis, in part due to limited activity of existing therapy. Primary therapy is largely dictated by the anatomical origin of the cancer and whether distant disease is present. Many patients with localized disease are treated with chemoradiotherapy, either in the definitive or adjuvant setting, and those with metastatic disease are treated with palliative chemotherapy. The chemotherapy used in SCCHN can be toxic, whether given with radiation or alone. The epidermal growth factor receptor (EGFR) is highly expressed in SCCHN and serves as a logical therapeutic target. EGFR-directed monoclonal antibodies (MoAbs) have higher activity in SCCHN than small molecule tyrosine kinase inhibitors. Cetuximab, a widely studied EGFR MoAb, is FDA approved in the metastatic setting, as well as with radiation for locally advanced disease. Despite improvements in survival when cetuximab is incorporated with chemotherapy for metastatic disease, the prognosis of patients remains poor. Novel EGFR MoAbs are being developed with the goal of improving efficacy and tolerability. This paper will summarize the use of EGFR-directed MoAbs in treating SCCHN with a focus on novel agents being tested.
format Online
Article
Text
id pubmed-3465896
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34658962012-10-10 EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab Kono, Scott A. Haigentz, Missak Yom, Sue S. Saba, Nabil Chemother Res Pract Review Article Squamous cell carcinoma of the head and neck (SCCHN) is a prevalent disease both in the United States and worldwide with an overall poor prognosis, in part due to limited activity of existing therapy. Primary therapy is largely dictated by the anatomical origin of the cancer and whether distant disease is present. Many patients with localized disease are treated with chemoradiotherapy, either in the definitive or adjuvant setting, and those with metastatic disease are treated with palliative chemotherapy. The chemotherapy used in SCCHN can be toxic, whether given with radiation or alone. The epidermal growth factor receptor (EGFR) is highly expressed in SCCHN and serves as a logical therapeutic target. EGFR-directed monoclonal antibodies (MoAbs) have higher activity in SCCHN than small molecule tyrosine kinase inhibitors. Cetuximab, a widely studied EGFR MoAb, is FDA approved in the metastatic setting, as well as with radiation for locally advanced disease. Despite improvements in survival when cetuximab is incorporated with chemotherapy for metastatic disease, the prognosis of patients remains poor. Novel EGFR MoAbs are being developed with the goal of improving efficacy and tolerability. This paper will summarize the use of EGFR-directed MoAbs in treating SCCHN with a focus on novel agents being tested. Hindawi Publishing Corporation 2012 2012-09-27 /pmc/articles/PMC3465896/ /pubmed/23056941 http://dx.doi.org/10.1155/2012/901320 Text en Copyright © 2012 Scott A. Kono et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kono, Scott A.
Haigentz, Missak
Yom, Sue S.
Saba, Nabil
EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
title EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
title_full EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
title_fullStr EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
title_full_unstemmed EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
title_short EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
title_sort egfr monoclonal antibodies in the treatment of squamous cell carcinoma of the head and neck: a view beyond cetuximab
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465896/
https://www.ncbi.nlm.nih.gov/pubmed/23056941
http://dx.doi.org/10.1155/2012/901320
work_keys_str_mv AT konoscotta egfrmonoclonalantibodiesinthetreatmentofsquamouscellcarcinomaoftheheadandneckaviewbeyondcetuximab
AT haigentzmissak egfrmonoclonalantibodiesinthetreatmentofsquamouscellcarcinomaoftheheadandneckaviewbeyondcetuximab
AT yomsues egfrmonoclonalantibodiesinthetreatmentofsquamouscellcarcinomaoftheheadandneckaviewbeyondcetuximab
AT sabanabil egfrmonoclonalantibodiesinthetreatmentofsquamouscellcarcinomaoftheheadandneckaviewbeyondcetuximab